Baseline demographics and medical therapy of study population
| Baseline characteristic | Total N=26 | Placebo N=13 | Etanercept N=13 | p Value |
|---|---|---|---|---|
| Age, years | 62±2 | 63±3 | 61±4 | 0.63 |
| Male, n (%) | 19 (73) | 10 (77) | 9 (69) | 0.66 |
| Time to randomisation (h)* | 67.9±7.8 | 70.5±8.1 | 64.7±14.5 | 0.32 |
| Peak troponin (ng/ml) | 8.3±2.3 | 8.9±3.8 | 7.7±2.5 | 0.79 |
| Cholesterol (mg/l) | 5.5±0.3 | 5.5±0.3 | 5.5±0.4 | 0.98 |
| Blood pressure (mm Hg) | 135/75±5/3 | 137/79±6/4 | 132/73±7/3 | >0.3 |
| Current smoker, n (%) | 6 (23) | 4 (31) | 2 (15) | 0.87 |
| Diabetes mellitus, n (%) | 2 (8) | 2 (15) | 0 (0) | 0.14 |
| Prior AMI, n (%) | 9 (35) | 5 (40) | 4 (35) | 0.68 |
| Hypertension, n (%) | 9 (35) | 5 (38) | 4 (31) | 0.68 |
| Hypercholesterolaemia, n (%) | 8 (31) | 5 (38) | 3 (23) | 0.40 |
| Aspirin, n (%) | 26 (100) | 13 (100) | 13 (100) | 1.0 |
| Clopidogrel, n (%) | 26 (100) | 13 (100) | 13 (100) | 1.0 |
| LMWH, n (%) | 22 (85) | 11 (85) | 11 (85) | 1.0 |
| ACE inhibitor, n (%) | 10 (42) | 7 (54) | 4 (31) | 0.43 |
| β Blocker, n (%) | 21 (88) | 9 (69) | 12 (92) | 0.14 |
| Statin, n (%) | 22 (85) | 10 (77) | 12 (92) | 0.28 |
| Ca channel antagonist, n (%) | 2 (8) | 0 (0) | 2 (15) | 0.14 |
Data expressed are means±SEM or the number of cases and percentage of the group. Groups are compared by a χ2 test or student t test for categorical and continuous data, respectively.
*Time to randomisation describes the interval between the onset of ischaemic symptoms and the first study blood sample.
AMI, acute myocardial infarction; LMWH, low molecular weight heparin.